Penumbra (Penumbra) Debt-to-Asset

: 0.15 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Penumbra's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13 Mil. Penumbra's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $221 Mil. Penumbra's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $1,556 Mil. Penumbra's debt to asset for the quarter that ended in Dec. 2023 was 0.15.

Penumbra Debt-to-Asset Historical Data

The historical data trend for Penumbra's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Penumbra Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.12

0.09

0.14

0.17

0.15

Penumbra Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset																0.17	0.17	0.16	0.16	0.15

Competitive Comparison

For the Medical Devices subindustry, Penumbra's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Penumbra Debt-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Penumbra's Debt-to-Asset falls into.

Penumbra Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Penumbra's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(13.434	+	220.909)	/	1556.305
	=	0.15

Penumbra's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(13.434	+	220.909)	/	1556.305
	=	0.15

Penumbra (NYSE:PEN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Penumbra Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Penumbra's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Penumbra (Penumbra) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

PEN:Mexico 0P8:Germany

Address

One Penumbra Place, Alameda, CA, USA, 94502

Website

https://www.penumbrainc.com

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Executives

Harpreet Grewal	director	C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Surbhi Sarna	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Johanna Roberts	officer: EVP, Gen. Counsel & Secretary	PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Bridget O'rourke	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Adam Elsesser	director, officer: Chairman, CEO and President	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Don W. Kassing	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Thomas Wilder	director	2 MUSICK, IRVINE CA 92618
Arani Bose	director, officer: Chief Innovator	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lynn Rothman	officer: EVP and Chief Business Officer	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
James Robert Pray	officer: President, International	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju	officer: CFO and Head of Strategy	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Maggie Yuen	officer: Chief Financial Officer	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Lambert Shiu	officer: Chief Accounting Officer	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Janet Leeds	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans	officer: EVP, Gen. Counsel & Secretary	ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502